- CDC estimates put the incidence of athlete concussion incidents at 5 to 10 percent of players
- Currently, there is no FDA-approved medicinal treatment for helping people with concussion injuries
- Odyssey Health Inc. is a company developing a drug-device combination to treat concussion patients in the first minutes after injury
- Retired pro soccer and football athletes Abby Wambach, Kurt Warner, and Brett Favre, have formed a Sports Advisory Board for Odyssey Health to help guide and promote public information regarding Odyssey’s treatment developments
- Wambach recently appeared on the Stock2Me podcast to discuss her interest in concussion research and her role on Odyssey’s sports board
The Center for Disease Control estimates that 5 to 10 percent of athletes will experience a concussion in any given sports season, marking the brain injury events as very common among athletes.
Soccer and football stand out as that may exact a heavy toll in traumatic brain injuries (“TBIs”) because of the way head and neck impacts form a part of the games.
The University of Michigan’s Health department cites statistics on the web page for its multidisciplinary NeuroSport program showing about 3.8 million concussions occur each year in the United States from sports-related injuries (https://ibn.fm/ywaND).
Retired pro soccer forward Abby Wambach and retired pro football quarterbacks Kurt Warner and Brett Favre have expressed hopes that medical science will yet be able to gain a better understanding of TBIs and how to treat them, particularly in regard to sports athletes.
The trio have expressed a willingness to let forensic researchers learn from their donated cadaver brains to advance medical science, and they have formed a Sports Advisory Board for Medical device innovator and biopharmaceutical product developer Odyssey Health (OTC: ODYY), a company that is preparing for human trials of a drug product-device combination it believes will ultimately help concussion-injured individuals to quickly heal and recover.
Currently, there is no medication approved by the U.S. Food and Drug Administration (“FDA”) for treating concussion injuries specifically, but Odyssey’s PRV-002 solution has shown promise and safe performance in animal testing. The human trial is enrolling volunteers to further establish the safety of Odyssey Health’s technology and is expected to then advance to a Phase II/III trial setup to show that PRV-002 technology is an effective option for concussed patients.
Wambach is an advocate for studying the differences between men and women in TBI vulnerability, degree of injury and measure of recovery since concussion-related attention generally focuses on men’s health (https://ibn.fm/Xts5H).
“In my retirement … I’ve had a lot of time to kind of reflect on the time that I played. I played soccer for 30 years and one of the biggest concerns that I have going into the rest of my life is my brain health,” Wambach told Stock2Me podcast host Stuart Smith in a July 13 interview (https://ibn.fm/PrSID).
“Of course, a lot of us really only think about concussions and CTE (chronic traumatic encephalopathy) as it relates to NFL football but the reality is brain trauma happens in every sport,” Wambach said. “And there’s just such little research done, not only on concussions themselves …, but also when you break it down into the genders of women and men, so many less dollars get siphoned over into the women’s side.”
Smith noted reports that show female athletes tend to be at much greater risk of traumatic brain injury events than male athletes and that they take longer to recover from them.
“It’s not just about how much the women are getting paid, it’s how these woman are getting treated off the field with travel arrangements, etc.,” Wambach said. “That has actually nothing to do with research in the medical fields on women’s bodies for things like concussions, for things like CTE. That’s why my role on this board is, I think, so important. … Not just (for) the sports community, because we’re talking about the military community as well; we’re talking about older folks taking a fall. Any person who is dealing with any kind of head trauma will greatly benefit from research, from the production of treatments like this medicine that Odyssey is behind.”
For more information, visit the company’s website at www.OdysseyHealthInc.com.
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.